Tumor Microenvironment‐Responsive PROTAC Prodrugs: A Pioneering Strategy for Precision Cancer Therapy
Advanced Functional Materials · 2026-05 · 36 (40)
DOI: 10.1002/adfm.202527321 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Functional Materials, online erschienen am 04.04.2026. Verfasst von Hong Yao und 6 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 120 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Qingdao Postdoctoral Science Foundation.
Abstract (Originalsprache)
The tumor microenvironment (TME) represents a highly specialized niche that not only supports malignant progression but also serves as a rich source of therapeutic targets. Characterized by distinctive pathophysiological features, including aberrant enzymatic activity, reductive stress, oxygen deprivation, and oxidative stress, the TME creates a unique biochemical landscape that can be exploited for targeted therapeutic interventions. In recent years, proteolysis‐targeting chimeras (PROTACs) have emerged as a revolutionary therapeutic paradigm in precision oncology, offering unprecedented capabilities for targeted protein degradation through hijacking the ubiquitin‐proteasome system. However, the clinical translation of conventional PROTACs faces significant challenges, particularly their inability to distinguish between malignant and healthy tissues, leading to potential off‐target effects and dose‐limiting toxicities. To address these limitations, a new generation of smart PROTAC prodrugs has been developed, designed to remain pharmacologically inert until selectively activated by TME‐specific stimuli. These innovative prodrug strategies employ various triggering mechanisms, including: (1) enzyme‐cleavable masking groups responsive to tumor‐associated proteases/esterases; (2) GSH‐sensitive disulfide linkages that exploit the reductive intracellular environment; (3) hypoxia‐activated prodrug moieties targeting oxygen‐deprived tumor regions; (4) ROS‐labile functional groups that respond to oxidative stress; and (5) pH‐responsive groups that react to the acidic TME. This comprehensive review systematically examines recent advances in TME‐responsive PROTAC prodrug design, with particular emphasis on structure‐activity relationships, activation kinetics, and therapeutic efficacy. Furthermore, we discuss emerging combination strategies that synergize TME‐responsive PROTACs with other treatment modalities, as well as current challenges and future directions in this rapidly evolving field.
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Qingdao Postdoctoral Science Foundation
- Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China
Zitieren
APA
Yao, H., Zhang, Y., Liu, M., Gao, S., Yang, J., Xing, D., & Wang, C. (2026). Tumor Microenvironment‐Responsive PROTAC Prodrugs: A Pioneering Strategy for Precision Cancer Therapy. Advanced Functional Materials, 36(40). https://doi.org/10.1002/adfm.202527321
Vancouver
Yao H, Zhang Y, Liu M, Gao S, Yang J, Xing D, et al. Tumor Microenvironment‐Responsive PROTAC Prodrugs: A Pioneering Strategy for Precision Cancer Therapy. Advanced Functional Materials. 2026;36(40). doi:10.1002/adfm.202527321
BibTeX
@article{Yao2026,
author = {Yao, Hong and Zhang, Yujing and Liu, Meng and Gao, Shan and Yang, Jinghua and Xing, Dongming and Wang, Chao},
title = {Tumor Microenvironment‐Responsive PROTAC Prodrugs: A Pioneering Strategy for Precision Cancer Therapy},
journal = {Advanced Functional Materials},
year = {2026},
volume = {36},
number = {40},
doi = {10.1002/adfm.202527321}
}
EUVIMED